Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
1,446
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Identifying possible germline variants from tumor-only sequencing of hematological malignancies

Jianming Shaoa Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Sishir Subedia Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Kristi Peppera Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Sabrina Badgetta Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Paul A. Christensena Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Heather L. Hendricksona Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TexasView further author information
,
Jessica S. Thomasa Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;b Weill Cornell Medical College, Cornell University, Houston, TexasView further author information
,
Randall J. Olsena Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;b Weill Cornell Medical College, Cornell University, Houston, TexasView further author information
&
Zejuan Lia Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;b Weill Cornell Medical College, Cornell University, Houston, TexasCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2714-8940View further author information
ORCID Icon show all
Pages 482-485 | Received 20 Jul 2020, Accepted 30 Sep 2020, Published online: 15 Oct 2020

References

  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(1):60–87.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Quinn E, Nichols KE. Cancer predisposition syndromes associated with myeloid malignancy. Semin Hematol. 2017;54(2):115–122.
  • Neben CL, Zimmer AD, Stedden W, et al. Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn. 2019;Jul21(4):646–657.
  • Ademuyiwa FO, Salyer P, Ma Y, et al. Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. Breast Cancer Res Treat. 2019;178(1):151–159.
  • LaDuca H, Polley EC, Yussuf A, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407–415.
  • Clifford M, Bannon S, Bednar EM, et al. Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies. Leuk Lymphoma. 2019;60(12):3020–3027.
  • Trottier AM, Cavalcante de Andrade Silva M, Li Z, et al. Somatic mutation panels: time to clear their names. Cancer Genet. 2019;235–236:84–92.
  • Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;18(9):825–835.
  • Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–2346.
  • Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018;2(2):146–150.
  • Li MM, Chao E, Esplin ED, et al. Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(7):1142–1148.
  • Guidugli L, Johnson AK, Alkorta-Aranburu G, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017;31(5):1226–1229.
  • Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4):424–432.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.